Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Triton BioSystems Inc.

Division of Aduro Biotech/Triton BioSystems Inc.

Latest From Triton BioSystems Inc.

Deal Watch: Bristol, Janssen Keep The Heat High In Cancer Immunotherapy Deal-Making

Bristol signs a licensing deal around CytomX’s Probody technology platform and becomes the third firm to set up a combination trial with Incyte’s IDO1 inhibitor. Janssen licenses novel immunotherapy candidates for prostate cancer from Aduro; Oncothyreon and Celldex arrange a combo trial in breast and ovarian cancer.

BioPharmaceutical Deals

Nanobiotix SA

Nanobiotix is taking advantage of the ability of nanoparticles to absorb and transform energy to treat cancer. The company's nanoXray technology uses standard x-ray to activate injected cell-targeting non-drug nanoparticles. Today, Nanobiotix is focused solely on cancer applications of its technology, but the company believes there are other targets for the technology, including cardiovascular diseases.
BioPharmaceutical Medical Device

What Nanotech Means to Health Care Investors

If there's a common theme being articulated by CEOs of nanobiotechnology start-ups, it's that, at least financially, life has been difficult because they're early stage. Indeed, the nanotech label is less significant to health care investors than considerations related to their business strategy. Drug-delivery-oriented nanobiotechs, for example, must be strongly product focused to avoid the implications that they have an old, low-value model.
BioPharmaceutical Medical Device

Triton BioSystems Inc.

Triton BioSystems eradicates tumors by using magnetic energy to heat up nano-sized iron oxide-based spheres that have localized in tumor tissue.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Aduro Biotech
  • Senior Management
  • Samuel Straface, PhD, Pres. & CEO
  • Contact Info
  • Triton BioSystems Inc.
    Phone: (978) 606-2900
    200 Turnpike Rd.
    Chelmsford, MA 01824